治疗时间已被确定为一个质量指标，治疗时间越长，结果越差。遗传评估是乳腺癌患者治疗咨询的一个组成部分。随着基因检测适应症的不断扩大，并考虑将基因检测扩大到所有有乳腺癌个人史的患者，本研究旨在评估基因评估对初次手术到手术时间间隔的影响。 2022 年 6 月至 2022 年 12 月期间接受 0-3 期乳腺癌的前期手术。获得了患者人口统计数据、治疗特征、国家综合癌症网络基因检测标准和结果。该研究包括 492 名患者（489 名女性）。 81 人 (16.2%) 诊断时年龄≤50 岁。总共有 281 名患者 (57.1%) 符合国家综合癌症网络基因检测标准，199 名患者 (72.4%) 接受了遗传咨询师的咨询。 76 名不符合国家综合癌症网络标准的患者 (27.6%) 寻求遗传咨询。总共有 218 名接受遗传咨询的患者 (79.3%) 完成了检测。基因检测结果的平均周转时间为 11 天（范围为 6-66 天）。 26 名患者 (11.9%) 具有致病性或可能致病性变异。其中 24 名患者符合国家综合癌症网络检测标准 (92.3%)，2 名患者不符合 (7.7%)。接受基因检测的患者的治疗时间为 33 天，而未进行基因检测的患者的治疗时间为 34 天 (P = .45)。三名具有致病性或可能致病性变异的患者（11.5%）由于基因检测结果而改变了最初的手术计划。七名术后返回致病性或可能致病性变异结果的患者没有接受额外的手术。在我们的研究队列中，遗传性乳腺癌评估和基因检测似乎没有延迟乳腺癌患者的治疗时间。版权所有 © 2023 Elsevier Inc. 所有权利预订的。

Time to treatment has been identified as a quality metric, with longer time to treatment associated with poorer outcomes. Genetic evaluation is an integral part of treatment counseling for patients with breast cancer. With expanding indications for genetic testing and consideration of expansion of genetic testing to all patients with a personal history of breast cancer, this study aims to evaluate the effect of genetic evaluation on the time interval from initial surgical visit to surgery.A retrospective review of patients undergoing upfront surgery for stage 0-3 breast cancer from June 2022 to December 2022. Patient demographics, treatment characteristics, National Comprehensive Cancer Network criteria for genetic testing, and results were obtained.The study included 492 patients (489 females). Eighty-one (16.2%) were ≤50 years of age at diagnosis. In total, 281 patients (57.1%) met National Comprehensive Cancer Network criteria for genetic testing and 199 consulted with a genetic counselor (72.4%). Seventy-six patients (27.6%) not meeting National Comprehensive Cancer Network criteria pursued genetic counseling. In total, 218 patients (79.3%) referred for genetic counseling completed testing. Mean turnaround time to genetic testing result was 11 days (range, 6-66 days). Twenty-six patients (11.9%) had a pathogenic or likely pathogenic variant. Twenty-four of these patients met National Comprehensive Cancer Network testing criteria (92.3%) and 2 did not (7.7%). The time to treatment for patients undergoing genetic testing was 33 vs 34 days in those without testing (P = .45). Three patients (11.5%) with pathogenic or likely pathogenic variants altered their initial surgical plan due to their genetic testing results. Seven patients with pathogenic or likely pathogenic variant results returning postoperatively did not undergo additional surgery.Hereditary breast cancer evaluation and genetic testing did not appear to delay time to treatment for patients with breast cancer in our study cohort.Copyright © 2023 Elsevier Inc. All rights reserved.